PIP-02: Protective Immunity Project 02
Study Details
Study Description
Brief Summary
Influenza (Flu) vaccine is recommended for kidney transplant patients who are at least 6 months post-transplant. The influenza vaccine stimulates the immune system to builds protective antibodies against the flu virus.
Previous research has shown that adult kidney transplant patients are not able to form as much of these protective antibodies as compared to healthy volunteers. Research has also suggested that different immunosuppressive medicines may have different effects on antibody formation. In this study, we hope to evaluate these differences in more detail.
In recent years, increasingly effective, but also increasingly complex, immunosuppressive regimens have been developed, however, there has been little detailed systematic study of the immune changes that occur in response to vaccination with these newer immunosuppressive regimens.Current policies on vaccination of transplant recipients are generic and continue to be based on old concepts rather than on any new understanding of the effects of these newer therapies on the immune system.
We hope to improve our understanding of the effects of the immunosuppressive regimens in use today (calcineurin-inhibitor, or CNI, and sirolimus-based regimens) on immune response to flu vaccine. Such knowledge will be critical to helping clinicians develop strategies for getting desirable immune responses while not causing rejection.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| tacrolimus Recipients of primary deceased or living donor renal transplant maintained on immunosuppressive regimen utilizing tacrolimus |
|
| sirolimus Recipients of primary deceased or living donor renal transplant maintained on immunosuppressive regimen utilizing sirolimus |
|
| Healthy controls Age, gender- and race-matched individuals, not on immunosuppressive medications |
Outcome Measures
Primary Outcome Measures
- To determine the effect of immunosuppressive regimens on the magnitude and character of the adaptive immune response to flu vaccine [7, 14, 28 and 90 days post vaccination]
- To determine the effects of chronic immunosuppressive therapies on innate immunity during response to flu vaccine [7, 14, 28 and 90 days post vaccination]
- To define the transcriptional and protein signatures of the response to flu vaccination in patients on conventional immunosuppressive regimens compared to healthy volunteers [7, 14, 28 and 90 days post vaccination]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Male or female patients between 18 and 59 years of age
-
Greater than six months post deceased or living donor renal transplant
-
Patients capable of understanding the purposes and risks of the study, who can give written informed consent and who are willing to participate in and comply with the study.
-
Patients with no known contraindications to flu vaccine (e.g. egg allergy, prior serious adverse reaction to flu vaccine, current febrile illness, marked leukopenia (WBC < 2500 cells/ml)
-
Women of childbearing potential must have a negative serum pregnancy test within 7 days of study enrollment and must not be breast-feeding.
Exclusion Criteria:
- Patients with evidence of an active systemic infection
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Emory University | Atlanta | Georgia | United States | 30322 |
Sponsors and Collaborators
- Emory University
Investigators
- Principal Investigator: Christian P. Larsen, MD, DPhil, Emory University
- Principal Investigator: Kenneth E Kokko, MD, PhD, Emory University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- IRB00024793
- PIP-02